文献速递流行病学与生物统计真实世界研究与卫生经济

2型糖尿病共病、死亡率与HbA1c:英国与台湾队列研究

Multimorbidity, mortality, and HbA1c in type 2 diabetes: A cohort study with UK and Taiwanese cohorts.
PubMed 文献 · PLoS Med · 2020-05-07

该研究基于英国生物银行(n=20,569)和台湾糖尿病管理项目(n=59,657)两个纵向队列,探讨2型糖尿病患者共病模式与基线HbA1c及全因死亡率的关系。结果显示,共病总数和不一致共病数增加与HbA1c降低和死亡率升高相关,且一致共病对死亡率的危害更大;与死亡率关联最强的共病组合在英国和台湾队列中存在差异。

要点

  • 2型糖尿病患者共病数量越多,HbA1c越低但全因死亡率越高。
  • 一致共病(与T2D相关)比不一致共病对死亡率的危害更大。
  • 死亡风险最高的共病组合在英国与台湾队列间存在差异。

核心结论

  • 在2型糖尿病患者中,共病总数和不一致共病数增加与HbA1c降低及全因死亡率升高相关。
  • 一致共病和不一致共病均与死亡率显著相关,但一致共病的风险比更大。
  • 与死亡率关联最强的共病组合在英国生物银行和台湾NDCMP之间存在差异。

研究设计与样本

  • 研究纳入英国生物银行(n=20,569)和台湾糖尿病管理项目(n=59,657)两个2型糖尿病纵向队列。
  • 共病 quantified 为除T2D外的疾病数量,分为总数、一致和不一致计数,并分析不同疾病组合。
  • 结局指标为基线HbA1c和全因死亡率。

主要发现

  • 台湾NDCMP中,与仅患T2D者相比,额外有4种及以上疾病者的HbA1c平均差异(95%CI)为-0.82%(-0.88,-0.76),p<0.001。
  • 英国生物银行中,与无共病者相比,额外有1、2、3、4种及以上疾病者的全因死亡率HR(95%CI)分别为1.20(0.91-1.56)、1.75(1.35-2.27)、2.17(1.67-2.81)、3.14(2.43-4.03),均p<0.001。
  • 有4种及以上一致共病者死亡率超过5倍(HR 5.83,95%CI 4.28-7.93,p<0.001)。
  • 英国生物银行中,T2D合并冠心病和心力衰竭的组合对死亡率影响最大(HR 4.37,95%CI 3.59-5.32,p<0.001);台湾NDCMP中,疼痛性疾病合并酒精问题的组合影响最大(HR 4.02,95%CI 3.08-5.23,p<0.001)。
  • 在英国生物银行,与死亡率关联最强的20种组合中有18种包含心血管疾病;在台湾NDCMP中,最强组合中有12种包含心血管疾病。

临床怎么用

  • 临床管理2型糖尿病时应评估共病总数及类型,尤其关注一致共病,以识别死亡高风险患者。
  • 不能仅凭HbA1c降低判断病情控制良好,需结合共病负担综合评估死亡风险。
  • 共病模式存在人群差异,个性化管理需考虑不同种族/地区的共病组合特点。

局限性

  • 研究无法对研究期间共病的变化进行建模。
  • 研究为观察性队列,不能推断因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is emerging interest in multimorbidity in type 2 diabetes (T2D), which can be either concordant (T2D related) or discordant (unrelated), as a way of understanding the burden of disease in T2D. Current diabetes guidelines acknowledge the complex nature of multimorbidity, the management of which should be based on the patient's individual clinical needs and comorbidities. However, although associations between multimorbidity, glycated haemoglobin (HbA1c), and mortality in people with T2D have been studied to some extent, significant gaps remain, particularly regarding different patterns of multimorbidity, including concordant and discordant conditions. This study explores associations between multimorbidity (total condition counts/concordant/discordant/different combinations of conditions), baseline HbA1c, and all-cause mortality in T2D. METHODS AND FINDINGS: We studied two longitudinal cohorts of people with T2D using the UK Biobank (n = 20,569) and the Taiwan National Diabetes Care Management Program (NDCMP) (n = 59,657). The number of conditions in addition to T2D was used to quantify total multimorbidity, concordant, and discordant counts, and the effects of different combinations of conditions were also studied. Outcomes of interest were baseline HbA1c and all-cause mortality. For the UK Biobank and Taiwan NDCMP, mean (SD) ages were 60.2 (6.8) years and 60.8 (11.3) years; 7,579 (36.8%) and 31,339 (52.5%) were female; body mass index (BMI) medians (IQR) were 30.8 (27.7, 34.8) kg/m2 and 25.6 (23.5, 28.7) kg/m2; and 2,197 (10.8%) and 9,423 (15.8) were current smokers, respectively. Increasing total and discordant multimorbidity counts were associated with lower HbA1c and increased mortality in both datasets. In Taiwan NDCMP, for those with four or more additional conditions compared with T2D only, the mean difference (95% CI) in HbA1c was -0.82% (-0.88, -0.76) p < 0.001. In UK Biobank, hazard ratios (HRs) (95% CI) for all-cause mortality in people with T2D and one, two, three, and four or more additional conditions compared with those without comorbidity were 1.20 (0.91-1.56) p < 0.001, 1.75 (1.35-2.27) p < 0.001, 2.17 (1.67-2.81) p < 0.001, and 3.14 (2.43-4.03) p < 0.001, respectively. Both concordant/discordant conditions were significantly associated with mortality; however, HRs were largest for concordant conditions. Those with four or more concordant conditions had >5 times the mortality (5.83 [4.28-7.93] p <0.001). HRs for NDCMP were similar to those from UK Biobank for all multimorbidity counts. For those with two conditions in addition to T2D, cardiovascular diseases featured in 18 of the top 20 combinations most highly associated with mortality in UK Biobank and 12 of the top combinations in the Taiwan NDCMP. In UK Biobank, a combination of coronary heart disease and heart failure in addition to T2D had the largest effect size on mortality, with a HR (95% CI) of 4.37 (3.59-5.32) p < 0.001, whereas in the Taiwan NDCMP, a combination of painful conditions and alcohol problems had the largest effect size on mortality, with an HR (95% CI) of 4.02 (3.08-5.23) p < 0.001. One limitation to note is that we were unable to model for changes in multimorbidity during our study period. CONCLUSIONS: Multimorbidity patterns associated with the highest mortality differed between UK Biobank (a population predominantly comprising people of European descent) and the Taiwan NDCMP, a predominantly ethnic Chinese population. Future research should explore the mechanisms underpinning the observed relationship between increasing multimorbidity count and reduced HbA1c alongside increased mortality in people with T2D and further examine the implications of different patterns of multimorbidity across different ethnic groups. Better understanding of these issues, especially effects of condition type, will enable more effective personalisation of care.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Chiang JI, Hanlon P, Li TC, et al. Multimorbidity, mortality, and HbA1c in type 2 diabetes: A cohort study with UK and Taiwanese cohorts. PLoS Med. 2020. PMID: 32379755. doi:10.1371/journal.pmed.1003094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。